SCHEDULE 13G/A: Farallon Capital Group Discloses 7.6% Stake in Lantheus Holdings, Inc.

Farallon Capital and its affiliated entities have filed an amended Schedule 13G, revealing a collective beneficial ownership of 7.6% of Lantheus Holdings, Inc.'s common stock as of December 31, 2024.

Summary

• Farallon Capital Partners, L.P., along with several other Farallon Capital affiliated funds and their general partners and managing members (collectively, the "Reporting Persons"), have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Lantheus Holdings, Inc.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 5,316,227 shares of Lantheus Holdings, Inc. Common Stock.
• This aggregate beneficial ownership represents 7.6% of the outstanding Common Stock of Lantheus Holdings, Inc.
• Farallon Partners, L.L.C., as the general partner for most of the Farallon Funds, is deemed to beneficially own 5,177,938 shares, representing 7.4% of the class.
• Farallon Healthcare Partners Master, L.P. holds 3,184,184 shares, accounting for 4.6% of the class.
• Farallon Capital Offshore Investors II, L.P. holds 883,013 shares, representing 1.3% of the class.
• Individual managing members and senior managing members of Farallon Capital's general partners, including Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, and others, are deemed to beneficially own the aggregate 5,316,227 shares, representing 7.6% of the class, due to their investment discretion.
• The filing indicates that the shares were not acquired for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or forward-looking statements that would indicate a strong positive or negative sentiment. The sentiment is neutral as it is a compliance filing.

Positives

• The disclosure of a significant stake by a prominent investment firm like Farallon Capital could be interpreted as a vote of confidence in Lantheus Holdings, Inc.'s long-term prospects and valuation.

Negatives

• NA

Risks

• NA

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Lantheus Holdings, Inc.'s future financial performance or strategic outlook. It solely reports beneficial ownership information.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Reporting Persons)

Industry Context

This filing is a routine disclosure of a significant passive investment by an institutional investor in a publicly traded company within the healthcare sector. It does not provide specific insights into broader industry trends or competitive dynamics, but rather reflects an investment decision by Farallon Capital.

Management Changes

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake can influence market perception and potentially provide a signal of confidence in the company's value. It also identifies a major shareholder whose interests may align or diverge with other shareholders.

Key Dates

Keywords

Lantheus Holdings Inc., Farallon Capital, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, Healthcare, Pharmaceuticals